UniProtKB/Swiss-Prot O43556: Variant p.His60Pro

Epsilon-sarcoglycan
Gene: SGCE
Chromosomal location: 7q22
Variant information

Variant position:  60
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Histidine (H) to Proline (P) at position 60 (H60P, p.His60Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (H) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In DYT11; affects protein stability; the mutant undergoes endoplasmic reticulum-associated degradation.
Any additional useful information about the variant.



Sequence information

Variant position:  60
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  437
The length of the canonical sequence.

Location on the sequence:   IFSKVHSDRNVYPSAGVLFV  H VLEREYFKGEFPPYPKPGEI
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IFSKVHSDRNVYPSAGVLFVHVLEREYFKGEFPPYPKPGEI

Mouse                         LFSKVHSDRNVYPSAGVLFVHVLEREYFKGEFPPYPKPGEV

Rat                           LFSKVHSDRNVYPSAGVLFVHVLEREYFKGEFPPYPKPGEV

Bovine                        IFSKVHSDRNVYPSAGVLFVHVLEREYFKGEFPPYPKPGEI

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 437 Epsilon-sarcoglycan
Topological domain 1 – 317 Extracellular


Literature citations

Myoclonus-dystonia: detection of novel, recurrent, and de novo SGCE mutations.
Hedrich K.; Meyer E.M.; Schule B.; Kock N.; de Carvalho Aguiar P.; Wiegers K.; Koelman J.H.; Garrels J.; Durr R.; Liu L.; Schwinger E.; Ozelius L.J.; Landwehrmeyer B.; Stoessl A.J.; Tijssen M.A.; Klein C.;
Neurology 62:1229-1231(2004)
Cited for: VARIANT DYT11 PRO-60;

A gain-of-glycosylation mutation associated with myoclonus-dystonia syndrome affects trafficking and processing of mouse epsilon-sarcoglycan in the late secretory pathway.
Waite A.; De Rosa M.C.; Brancaccio A.; Blake D.J.;
Hum. Mutat. 32:1246-1258(2011)
Cited for: CHARACTERIZATION OF VARIANTS DYT11 ARG-60; PRO-60; THR-92; CYS-115; ARG-270 AND TYR-271;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.